Enhancer ID: | E_01_0594 |
Species: | human |
Position : | chr1:8002032-8004032 |
Biosample name: | |
Experiment class : | High+Lowthroughput |
Enhancer type: | Enhancer |
Disease: | Triple-negative breast cancer |
Pubmed ID: | 32432675 |
Enhancer experiment: | qPCR?ChIP-seq |
Enhancer experiment description: | Taken together, our findings suggest that the progressive loss of the GC-dependent regulation and anti-tumorigenic function of ERRFI1 influences BCa progression and may contribute to the unfavorable effects of GC therapy in TNBC. |
Target gene : | ERRFI1 |
Strong evidence: | qRT-PCR,qPCR,ChIP,3C |
Less strong evidence: | RNA-Seq |
Target gene experiment description: | Taken together, our findings suggest that the progressive loss of the GC-dependent regulation and anti-tumorigenic function of ERRFI1 influences BCa progression and may contribute to the unfavorable effects of GC therapy in TNBC. |
TF name : | -- |
TF experiment: | qPCR?ChIP-seq |
TF experiment description: | Taken together, our findings suggest that the progressive loss of the GC-dependent regulation and anti-tumorigenic function of ERRFI1 influences BCa progression and may contribute to the unfavorable effects of GC therapy in TNBC. |
Enhancer function : | Taken together, our findings suggest that the progressive loss of the GC-dependent regulation and anti-tumorigenic function of ERRFI1 influences BCa progression and may contribute to the unfavorable effects of GC therapy in TNBC. |
Enhancer function experiment: | Immunohistochemical staining |
Enhancer function experiment description: |
Taken together, our findings suggest that the progressive loss of the GC-dependent regulation and anti-tumorigenic function of ERRFI1 influences BCa progression and may contribute to the unfavorable effects of GC therapy in TNBC. |
SNP ID: | -- |
GeneName | Pathway Name | Source | Gene Number |
---|